Genomic Health Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported total revenues of $101,258,000 compared to $83,821,000 a year ago. Income from operations was $11,758,000 compared to loss from operations of $2,632,000 a year ago. Income before income taxes was $12,600,000 compared to loss before income taxes of $2,029,000 a year ago. Net income was $12,225,000 or $0.32 per diluted share compared to loss of $2,191,000 or $0.06 per basic and diluted share a year ago. Non-GAAP income from operations was $12,927,000 compared to $617,000 a year ago. Non-GAAP net income was $13,338,000 compared to $1,058,000 a year ago.

For the nine months, the company reported total revenues of $289,502,000 compared to $253,287,000 a year ago. Income from operations was $14,470,000 compared to loss from operations of $8,600,000 a year ago. Income before income taxes was $17,601,000 compared to loss before income taxes of $4,374,000 a year ago. Net income was $16,767,000 or $0.45 per diluted share compared to loss of $5,736,000 or $0.17 per basic and diluted share a year ago. Non-GAAP income from operations was $26,489,000 compared to non-GAAP loss from operations of $5,351,000 a year ago. Non-GAAP net income was $27,320,000 compared to non-GAAP net loss of $4,473,000 a year ago.

For the full year, the company expects to deliver revenue  growth of 17% in 2018, surpassing both the top-end of original revenue  guidance for the full year and annual revenue  growth goal of 15%. The company is raising revenue  and net income  guidance for the full year ending December 31, 2018, which assumes 17% to 19% year-over-year revenue  growth in the fourth quarter and 14th consecutive quarter of improved non-GAAP profitability . The company expects revenue of $389 million to $391 million compared to the former guidance of $366 million to $382 million. Net Income  (GAAP) is expected to be $26 million to $28 million compared to the former guidance of $0 million to $5 million. GAAP Basic EPS  is expected to $0.72 to $0.78 compared to the former guidance of $0.0 to $0.14. Net Income  (Non-GAAP) is expected to be $37 million to $39 million compared to the former guidance of $14 million to $20 million. Non-GAAP Basic EPS is expected to $1.03 to $1.08 compared to the former guidance of $0.39 to $0.56.